Inhibitors of endo-exonuclease activity for treating cancer

Details Inhibitors of endo-exonuclease activity for treating cancer Inhibitors of endo-exonuclease activity for treating cancer

2006-10-03

2006-10-03

Low, Christopher S. F. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S631000, C514S634000, C514S643000

Reexamination Certificate

active

07115665

ABSTRACT:
The present invention relates to the treatment of cancer with compounds that inhibit the activity of endo-exonuclease. Endo-exonuclease has been shown to be necessary for the repair of damaged DNA. Compounds that inhibit the activity of endo-exonuclease have been shown to be particularly effective for treating cancer when used in combination with drugs that induce DNA breaks such as cisplatin and mitomycin C. These compounds have a synergistic effect when used in combination for inhibiting tumour growth. The invention includes pharmaceutical compositions for inhibiting tumour growth comprising a compound that inhibits endo-exonuclease activity. These pharmaceutical compositions preferably include compounds that induce DNA breaks. The invention includes methods of treating cancer with these pharmaceutical compositions and uses of these compositions to treat cancer. The preferred compounds that inhibit the activity of endo-exonuclease have low toxicity. One such compound is pentamidine. The invention also includes a method for diagnosing cancer and monitoring its progression. This aspect of the invention involves isolating serum from a patient; measuring the concentration of endo-exonuclease in said serum and determining whether said concentration is above a predetermined mean.

REFERENCES:
patent: 5037758 (1991-08-01), Mulligan et al.
patent: 5084480 (1992-01-01), Pai et al.
patent: 5089527 (1992-02-01), Lord
patent: 5166140 (1992-11-01), Scanlon et al.
patent: 5204113 (1993-04-01), Hartley et al.
patent: 5204352 (1993-04-01), Sundberg et al.
patent: 5283238 (1994-02-01), Potempa et al.
patent: 5324830 (1994-06-01), Resnick et al.
patent: 5334374 (1994-08-01), Hartley et al.
patent: 5334522 (1994-08-01), Resnick et al.
patent: 5352581 (1994-10-01), Resnick et al.
patent: 5362489 (1994-11-01), Kishimoto et al.
patent: 5489524 (1996-02-01), Resnick et al.
patent: 5541088 (1996-07-01), Kishimoto et al.
patent: 5585363 (1996-12-01), Scanlon et al.
patent: 5698556 (1997-12-01), Chan
patent: 5723288 (1998-03-01), Dykstra et al.
patent: 5792782 (1998-08-01), Dykstra et al.
patent: 5817686 (1998-10-01), Dykstra et al.
patent: 5817687 (1998-10-01), Dykstra et al.
patent: 5874283 (1999-02-01), Harrington et al.
patent: 5916779 (1999-06-01), Pearson et al.
patent: 5935982 (1999-08-01), Dykstra et al.
patent: 5939440 (1999-08-01), Dykstra et al.
patent: 6017941 (2000-01-01), Dykstra et al.
patent: 6156779 (2000-12-01), Dykstra et al.
patent: 8016062 (1996-01-01), None
patent: 2819041 (1998-10-01), None
patent: WO 91/07180 (1991-05-01), None
patent: WO 94/01566 (1994-01-01), None
patent: WO 96/18725 (1996-06-01), None
patent: WO 98/13509 (1998-02-01), None
patent: WO 98/46755 (1998-10-01), None
patent: WO 99/12557 (1999-03-01), None
patent: WO 99/14328 (1999-03-01), None
patent: WO 99/18126 (1999-04-01), None
patent: WO 99/24603 (1999-05-01), None
patent: WO 99/25386 (1999-05-01), None
Snapper, Isadore. “Stilbamidine and Pentamidine in Multiple Myeloma,” J.A.M.A.(1947) 133(3): 157-161.
Perez et al. “Binding of Pt-pentamidine to mucleosomal DNA: Studies of the antiproliferative acticity of the drug against human cancer cells.” Chemico-Biological Interactions (1993) 89: 61-72.
Cecil Textbook of Medicine, 21st ed., vol. 1, Goldman et al. (eds.), published 2000 by W.B. Saunders Company, p. 1060-1074.
Stedman's Medical Dictionary, 25th edition, published 1990 by Williams & Wilkins, p. 1013.
Asefa, B., et al., “Genetic Analysis of the Yeast NUD1 Endo-exonuclease: a Role in the Repair of DNA Double-Strand Breaks”,Curr. Genet1998, 34, pp. 360-367.
Bailly, C., et al., “Sequence-selective Binding to DNA of bis(amidinophenoxy)alkanes Related to Propamidine and Pentamidine”,Biochem J., 1977, 323, pp. 23-31.
Borst, P., “Metabolism and Chemotherapy of African Trypanosomes”,Transactions of the Royal Society of Tropical Medicine and Hygiene, 1977, 71(1), pp. 3-4.
De Luca, et al., Anti-Sense Oligonucleotides Directed against EGF-Related Growth Factors Enhance Anti-Proliferative Effect of Conventional Anti-Tumor Drugs in human Colon Cancer Cells,Int. J. Cancer, 1997, 73, pp. 277-282.
Del Poeta, et al., “Structure—In Vitro Activity Relationships of Pentamidine Analogues and Dication-Substituted Bis-Benzimidazoles as New Antifungal Agents”,Antimicrobial Agents and Chemotherapy, 1998, 42(10), pp. 2495-2502.
Hildebrant, E., et al., “Identification and Characterization of an Deno-Exonuclease inPneumocystis cariniithat is Inhibited by dicationic Diaryfurans with Efficacy AgainstPneumocystisPenumonia”,J Euk. Microbiol, 1998, 45(1), pp. 112-121.
Kidani, Y., et al., “Synthesis of Platinum (II) Complexes of 4-Substituted o-Phenylenediamine Derivaties and Determination of Their Antitumor Activity”,Chem., Pharm. Bull., 1979, 27(11), pp. 2577-2581.
Perez, JM, et al., “Binding of Pt-Pentamidine to Nucleosomal DNA . . . ”,Chemico-Biological Interactions, 1993, 89, pp. 61-72.
Perez, JM, et al., “DNA Binding Properties and Antileukemic (L1210) Activity of a Pt-Pentamidine Complex”,Chem-Biol Interactions, 1991, 77, pp. 341-355.
Reisner, et al., “Immunoassays for Pentamidine an Related Compounds: Development of a Facile Inhibitory ELISA Suitable for Clinical use”,J. Clin. Lab. Anal., 2000, 14(2), pp. 73-82.
Tanious, FA, et al., “Effects of Compound Structure on Carbazole Dication-DNA Complexes,”Biochem, 2002, 39, pp. 2091-12101.
Tuan, IZ, et al., “Pneumocystis cariniiPneumonitis Following Bone Marrow Transplantation”,Bone Marrow Transplantation, 1992, 10, pp. 267-272.
Waalkes, TP, et al., “Pentamidine: Clinical Pharmacologic Correlations in Man and Mice”,Clinical Pharmacology and Therp., 1970, 11(4), pp. 505-512.
Snapper, Isidore, “Stilbamidine and Pentamidine in Multiple Myeloma”, J.A.M.A. Jan. 18, 1947, vol. 133, No. 3, p. 157-161.
DiMarco, A., Gaetani, M., Orezzi, P., Scotti, T., Arcamone, F. “Experimental Studies on Distamycin A—A New Anitbiotic with Cytotoxic Activity”, Cancer Chemotherapy Reports, No. 18, May 1962, p. 15-19, XP009045455.
Makulu et al., Effects of Pentamidine Upong Murine Leukemia and the Walker 256 Carcinoma (W256), Cancer Chemotherapy I, Aug. 18, 1974, p. 105.
Brewer, Angus E., “Multiple Myeloma Treated With Stilbamidine and Pentamidine”, British Medical Journal, Dec. 4, 1948, vol. II, p. 978-982.
Bertino, Joseph R. et al., “Principles of Cancer Therapy”, Textbook of Medicine, 21st Edition, vol. 1, xiv Oncology, p. 1060-1074.
Pathak, Manas, “Pentamidine is an Inhibitor of PRL Phosphatases with Anticancer Activity” Molecular Cancer Therapeutics, Dec. 2002, vol. 1, p. 1255-1264.
Gallioo, Dott. Edoardo, “I moderni orientamenti della chemioterapia dei tumori”, Minerva Medica, 1952 43 (99) Dec. 6th, p. 1264-1278.
Rondoni, Prof. P. “Relazione Sull'Attivita Dell Istituto Naz Per Lo Studio e la Dei Tumori Di Milano Per L'Anno 1948” Tumori, 1949, 23:92-99.
Alwall, Nils, “Urethane and Stilbamidine in Multiple Myeloma”, The Lancet, Sep. 13, 1947, vol. 2, p. 388-389.
Dubois-Ferriere, Par H., “La therapeutique du myelome multiple”, Praxis, Jan. 8, 1948, No. 3, p. 42-44.

Affiliated with

Also associated with

Rating

Inhibitors of endo-exonuclease activity for treating cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of endo-exonuclease activity for treating cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of endo-exonuclease activity for treating cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3639997